20/20 BioLabs Sees 17% Revenue Growth and Raises $5M in Private Placement
20/20 BioLabs recorded $2.0 million in 2025 revenue, up 17%, with gross margin of 29.6%, a 900-basis-point expansion. Net loss narrowed 33% to $3.7 million, and a $5.0 million private placement plus $520,000 state grant and Medicare MCED reimbursement pathway support 2026 growth.
1. Financial Performance Highlights
In 2025, the company generated $2.0 million in revenue, a 17% increase from 2024, and delivered gross profit of $0.6 million, a 68% rise. Gross margin expanded by 900 basis points to 29.6%, operating expenses declined 35% to $3.9 million, and net loss narrowed by 33% to $3.7 million.
2. Operational and Strategic Initiatives
The company launched its OneTest™ for Longevity chronic disease solution with IBM AI integration and secured an exclusive U.S. license with ROKIT Healthcare for CKD prediction technology. It also received $520,000 in funding for firefighter cancer screenings using its OneTest™ MCED blood test in Maryland.
3. Financing and Capital Position
On February 19, 2026, the company completed a $5.0 million private placement under a preferred purchase agreement allowing up to $40 million in future tranches. Deferred revenue reached approximately $0.4 million at year-end, and the cash balance stood at $1.0 million after reducing net cash used in operations to $1.9 million.
4. Future Outlook and Medicare Legislation
Following the Medicare Multi-Cancer Early Detection Screening Act establishing a reimbursement pathway by 2028, management expects accelerated demand. With Nasdaq listing completed in February 2026, the company targets growth in firefighting, veterans, occupational health and direct-to-consumer channels throughout 2026.